Europlasma Société Anonyme announced audited consolidated earnings results for the year ended December 31, 2015. Consolidated revenue amounted to €14.1 million for the 2015 financial year against €8.983 million a year ago. The €5.1 million increase, that is 57% for the year, was driven by revenue growth in each of the Group's segments.

The operating loss for 2015 stood at €14.6 million against €22.940 million a year ago. The €8.3 million improvement compared with 2014 is due, on the one hand, to a significant reduction in depreciation, amortisation, impairment and provisions over the period, and on the other hand, to the more solid operating performance. LBITDA was €9 million compared with €11.2 million in 2014.

This improvement in performance was driven by each of the segments, which all posted positive contributions to this change. In total, the loss is standing at €16.2 million, compared with €26 million in 2014, a reduction of 38%. Net debt was €5,709,000.

Net cash used in operating activities was €11.996 million compared with €13.083 million in 2014.